Mizoribine Versus Mycophenolate Mofetil in Combination Therapy With Tacrolimus for De Novo Kidney Transplantation: Evaluation of Efficacy and Safety

Ju, Man Ki; Huh, Kyu Ha; Park, K.T.; Kim, S.J.; Cho, B.H.; Kim, C.D.; So, Byung Jun; Kang, Chong Myung; Lee, S.; Joo, Dong Jin; Kim, Y.S.

doi:10.1016/j.transproceed.2012.12.028

Cited by 8 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of interest is the use of Mz, which has a similar mechanism of action to MMF, as part of maintenance immunosuppressive therapy, which is effective in achieving early restoration of transplant kidney function [21,22]. Mz has been shown to suppress macrophage activation, including preventing glucocorticoid-induced M2-type macrophage polarization and glomerulosclerosis in experimental glomerulonephritis [11].…”

Section: Discussionmentioning

confidence: 99%

Alternatively activated macrophages in the pathogenesis of chronic kidney allograft injury

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Alternatively activated macrophages in the pathogenesis of chronic kidney allograft injury

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Mizoribine has a potential advantage over rapamycin and its analogs, which are often used for treating TSC and LAM lesions, in its ability to induce tumor cell death and correspondingly slow the rate of tumor regrowth if treatment is discontinued. Importantly, decades of clinical use of mizoribine indicate that it has a safety profile in humans that is similar or favorable to mycophenolate and rapamycin (23,42,44,45).…”

Section: Discussionmentioning

confidence: 99%

IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex

Valvezan¹,

McNamara²,

Miller³

et al. 2020

JCI Insight

View full text Add to dashboard Cite

“…Of the identified articles, 125 were duplicates and removed, 789 articles were excluded after reading the titles and abstracts. After the full-texts screening, 12 RCTs, including 1103 patients, met the inclusion criteria and were then included in this meta-analysis [15][16][17][18][19][20][21][22][23][24][25][26]. e details of our literature search and selection process are shown in Figure 1.…”

Section: Search Processmentioning

confidence: 99%

The Efficacy and Safety of Mizoribine versus Mycophenolate Mofetil for the Treatment of Renal Transplantation: A Systematic Review and Meta-Analysis

Chen

Liu

Yin

et al. 2022

Computational Intelligence and Neuroscience

View full text Add to dashboard Cite

Background. Mizoribine (MZR) is widely used in Asia due to its high safety and low cost, and comparative studies of its safety and efficacy with the first-line drug mycophenolate mofetil (MMF) have been carried out. This paper aimed to compare the efficacy and safety of MZR and MMF in immunosuppressive therapy of renal transplantation by meta-analysis. Methods. We searched randomized controlled trials (RCTs) comparing MZR versus MMF for renal transplantation in PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, WanFang Database, China National Knowledge Infrastructure (CNKI), and Chinese Biomedical Database (CBM). Articles were assessed for their risk of bias using the Cochrane Collaboration. Forest plots and funnel plots were also performed on the included articles. Results. A total of twelve studies with 1103 patients were selected in the analysis. No significant difference were observed between the MZR group and the MMF group for the rate of acute rejection (RR = 1.50, 95% CI 1.11 to 2.01, P = 0.008), patient survival (RR = 1.01, 95% CI 0.99 to 1.03, P = 0.56), graft survival (RR = 1.02, 95% CI 1.00 to 1.04, P = 0.12), leucopenia (RR = 0.69, 95% CI 0.44 to 1.10, P = 0.12), and liver damage (RR = 0.72, 95% CI 0.46 to 1.13, P = 0.15). The MZR group was associated with a lower risk of gastrointestinal disorder (RR = 0.28, 95% CI 0.13 to 0.62, P = 0.002) and cytomegalovirus infection (RR = 0.59, 95% CI 0.42 to 0.84, P = 0.003) but had a higher risk of hyperuricemia (RR 1.79, 95% CI 1.17 to 2.75, P = 0.007). No significant publication bias was observed among included studies. Discussion. MZR is similar to MMF in efficacy, and in terms of safety, MZR has a lower risk of gastrointestinal disorder and cytomegalovirus infection but a higher risk of hyperuricemia.

show abstract

Mizoribine Versus Mycophenolate Mofetil in Combination Therapy With Tacrolimus for De Novo Kidney Transplantation: Evaluation of Efficacy and Safety

Cited by 8 publications

References 12 publications

Alternatively activated macrophages in the pathogenesis of chronic kidney allograft injury

Alternatively activated macrophages in the pathogenesis of chronic kidney allograft injury

IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex

The Efficacy and Safety of Mizoribine versus Mycophenolate Mofetil for the Treatment of Renal Transplantation: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About